Praxis Ends Epilepsy Study Early Due to Strong Results, Heads to FDA
Praxis has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug candidate ulixacaltamide, for which an approval application is slated for early 2026.
Praxis Ends Epilepsy Study Early Due to Strong Results, Heads to FDA Read More »
